Lucid Diagnostics (NASDAQ:LUCD) Price Target Lowered to $2.00 at Cantor Fitzgerald

Lucid Diagnostics (NASDAQ:LUCD - Free Report) had its target price cut by Cantor Fitzgerald from $3.00 to $2.00 in a report published on Friday morning,Benzinga reports. They currently have an overweight rating on the stock.

A number of other brokerages have also commented on LUCD. Canaccord Genuity Group upgraded shares of Lucid Diagnostics to a "strong-buy" rating in a report on Tuesday, August 13th. Ascendiant Capital Markets cut their price target on Lucid Diagnostics from $7.50 to $7.25 and set a "buy" rating on the stock in a report on Tuesday, September 10th. Canaccord Genuity Group reiterated a "buy" rating and set a $3.00 price objective on shares of Lucid Diagnostics in a report on Thursday. Finally, Needham & Company LLC reissued a "buy" rating and issued a $2.50 target price on shares of Lucid Diagnostics in a research report on Thursday. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $3.69.

Lucid Diagnostics Price Performance

Shares of LUCD stock traded down $0.02 on Friday, reaching $0.99. 426,495 shares of the stock were exchanged, compared to its average volume of 195,200. Lucid Diagnostics has a one year low of $0.63 and a one year high of $1.58. The stock has a market cap of $53.28 million, a PE ratio of -0.88 and a beta of 1.41. The stock has a 50 day moving average price of $0.87 and a 200 day moving average price of $0.85.

Lucid Diagnostics (NASDAQ:LUCD - Get Free Report) last issued its earnings results on Monday, August 12th. The company reported ($0.23) earnings per share (EPS) for the quarter. The business had revenue of $0.98 million during the quarter. On average, research analysts expect that Lucid Diagnostics will post -0.82 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Lucid Diagnostics stock. Virtu Financial LLC lifted its stake in shares of Lucid Diagnostics Inc. (NASDAQ:LUCD - Free Report) by 66.4% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 34,671 shares of the company's stock after acquiring an additional 13,835 shares during the quarter. Virtu Financial LLC owned approximately 0.07% of Lucid Diagnostics worth $28,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 74.01% of the stock is owned by hedge funds and other institutional investors.

About Lucid Diagnostics

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.